Mobocertinib (TAK-788) is an oral tyrosine kinase inhibitor (TKI) that inhibits in-frame EGFRex20ins mutations in NSCLC with better potency and selectivity over wild-type (WT) EGFR than other TKIs, including erlotinib, gefitinib, afatinib, and osimertinib [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.